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Novavax Inc. and Generex Biotechnology Corp. led gains by biopharmaceutical
companies after the World Health Organization said seven Indonesians may
have contracted avian influenza from other humans. Bloomberg.com May 24th
2006.
Remington Arms Company: Stocks in this firearms manufacturer fell sharply after
it was discovered that the company’s previously announced ‘cure’ for the Avian
Flu was nothing more than the model 1100 Classic Trap Shotgun. The
Onion.com July 18th 2006.
The future of biotechnology is an increasingly emotive subject. It is also of growing interest to
geographers. From speculation about the risks to global biosecurity, the promise of safety
through biometric surveillance, the hope of new pharmaceuticals, the opportunities for
expanding agricultural production, or disgust at new forms of biological manipulation,
biotechnology is proceeding through a series of affective appeals to our deep-seated hopes
and fears. Such speculations also make claims about the kinds of spatialities we inhabit,
stressing the importance of borders, boundaries, enclosures and surveillance. If the recent
claims for future applications of the life sciences are amassed, we find our selves and our
bodies located at the centre of a global triage system, subject to a fantastical array of
technological devices, drug regimes, medical and agricultural products, which promise to treat
the ailments that define us, curing individual disease, protecting state security, or feeding the
world. Such biotechnological imaginaries define our pathologies, yet at the same time they
offer us hopes of salvation, or at least corporeal alleviation. The speculative business of
biotechnology is increasingly to ignite both our fears and our hopes at the same time.
Yet for all these heady emotions, I want to suggest that biotechnology is a funny business as
well. This too is a speculative claim, but it is an argument I want to try and make by drawing
on a different emotional repertoire: that of humour, irony and ambiguity. You’ll have to bear
with me, there isn’t a punchline. I’m also hesitant in my delivery. To point out the potential
comedy that comes with the conjoined narratives of danger and hope in biotechnological
discourses feels like tempting fate. I’ll be holding my breath until this comes to print and
maybe ruing it shortly after. The problem is that the avian flu virus will mutate, someone will
try and use some form of biological agent in a terrorist attack, there will be further unfortunate
deaths for those left in the wake of the pursuit of better medical treatment for the fortunate.
These things have happened before, and they will happen again. So where is the humour
here? Perhaps this is my point. The increasingly shrill speculations around the future of
biology have left little space for us to reflect outside of their anxious embrace, to question the
trajectory of particular pathogens through society, to chart alternative connections between
biology and the politics of health and security, to think differently about strategies for
cultivating the well-being of all kinds of organisms. We both fear and desire change, and the
promissory futures of biotechnology draw affectively on these fears and fetishes. A little
humour might enable us the space to think differently.
So why is this a pertinent issue now? There are a few developments in the life sciences that
mean the material effect of these speculative discourses is increasing. The impact that
expectations have in directing the development of any particular technology are now well
documented in what science and technology studies call the sociology of expectations (Brown
and Michael 2003). Such reviews show us what is at stake in defining a technology as
something new, or alternatively locating it within established trajectories (Jasanoff 2005). It
also shows us how expectations in biotechnology have changed over time. That is, the way
the future was once represented is different to the way it has been represented more recently
(Brown and Michael 2003). This is in large part due to the growth of scientists as
entrepreneurs as well as researchers. In standing to benefit from a short term rise in stock
value, there are now more incentives to make strong claims about the future, notwithstanding
the uncertainties evident in current research activity or the indeterminacies of long term
performance. This then links to a further form of analysis, about the particular salience of
speculative capital at this historical moment (Cooper 2006a, Sunder Rajan, forthcoming).
Speculation is not new to capitalism. What is crucial to the analysis here is that speculation
appears to be both more intense and at the same time less coupled to a material basis in
profit than at any other time in the history of capitalism. As Kaushik Sunder Rajan puts it, ‘it is
not that abstraction replaces materialism, but rather that the abstractions that represent value
are more and more distantly coupled (ontologically and temporally) from their materialist
bases’ (forthcoming).
It is also possible to suggest there are changes in the tropes through which biotechnological
speculation is operating. Going back to Mulkay’s classic analysis of the rhetorics of hope and
fear in analysis of debates over embryo research, there are hopes expressed around these
new technologies, and so too there are fears (Mulkay, 1993). These dualities still exist. But
what seems of increasing salience is appeal to a more brutal form of biopolitical rhetoric that
links discourses of bodily security explicitly to biotechnological futures. There is perhaps a
new rationality of life being forged in the response of biotechnology companies to what
Melinda Cooper has termed the ‘biological turn in the war on terror’ (Cooper, 2006b).
Security is increasingly defined in human and biological terms, and so biotechnological hopes
and fears are defined in concert, capitalizing on the opportunity to offer individuals and
governments protection in ways that militarize the politics of biotechnology, through new
drugs and new biosecurity regimes that seek to insulate human and animal populations from
exterior risks (see for example Braun, 2006). In the same way that Mulkay suggests the UK
parliamentary debates about embryology demonstrated the apparent unassailability of
representations that evoked ‘hope’ (Mulkay, 1993), so too these dual representations of hope
and fear can appear equally irrefutable, leaving little space for alternative voices.
Finally then, there is frustration that there is no obvious place to occupy which is outside of
these material and discursive circuits. Whilst it might be possible to explore the material
bases of such speculations, to seek to denaturalise these projects, their discourses cannot be
so easily discounted, for the reality of them operates precisely in the realm of potential, that is
the potential to materialise new markets (Sunder Rajan, forthcoming). It is not possible to
avoid the affective economies of hope and fear through which such promissory futures are
constructed. Speculation is a central performative repertoire in these contemporary bio-
economies and cannot be side-stepped by cynicism about the basis for making such claims;
rather a different form of engagement with the discourses, materiality, performativity and
accountability of speculation itself is required.
So what strategies are there to engage differently with these politics of biotechnological
speculation? It is perhaps too easy to be pulled into tracing the construction of these darkly
emergent worlds, following the science as it moves towards a teleological future and thus to
tell stories that accentuate their discursive force. I would tentatively suggest there are other
productive modes of engagement, which might both challenge and expand the scope of
biotechnological speculation, through seeking to capture our imaginations in different ways. If
engaging with affective economies of hope and fear, affect becomes a political strategy. And
in puncturing the apparently seamless construction of networks of biotechnological risk and
innovation, irony and humour are potentially transformative tools. As Donna Haraway puts it,
‘irony is about contradictions that do not resolve into larger wholes, even dialectically, about
the tension of holding incompatible things together because both or all are necessary and true.
Irony is about humour and serious play. It is also a rhetorical strategy and a political method.’
(Haraway, 1991, p.149). Recourse to a critical attitude and an absurdist humour might just be
a productive way to begin to open up spaces to see the politics of biology differently.
What I am not suggesting, however, is a distancing form of irony. Indeed, I want to suggest
we could usefully look first to the humour inherent within biology itself. Originally writing at the
end of the US involvement within Vietnam, and recently cited within Richard Mabey’s book of
reflections on nature and emotion (Mabey, 2006), the biologist Joseph Meeker suggests that
there is comedy within biological processes themselves. Evolution, he argues,
‘proceeds as an unscrupulous, opportunistic comedy, the object of which
appears to be the proliferation of as many life forms as possible. Successful
participants in it are those who live and reproduce even when times are
dangerous, not those who are best able to destroy enemies or competitors. Its
ground rules for participants, including people, are those that also govern literary
comedy; organisms must adapt themselves to their circumstances in every
possible way, must studiously avoid all or nothing choices, must seek
alternatives to death, must accept and revel in maximum diversity, must
accommodate themselves to the accidental limitations of birth and environment,
and must prefer cooperation to competition, yet compete successfully when
necessary […] Comedy is a strategy for living that contains ecological wisdom,
and it may be one of our best guides (Meeker, 1974, cited in Mabey, 2006,
p.200).
Comedy as a strategy for living eschews the essentialism and anthropocentrism that feature
in these linear narratives of biological risk, and challenges the emphasis on destruction in the
pursuit of purity that emerges frequently in biosecurity strategies. A few examples
demonstrate the diversity of paths that biological agents can take as they are woven into the
fabric of society and nature relations. Take for example the incongruous history of the
Botulinum Toxin, a neurotoxic protein produced by the bacteria Clostridium botulinum. It first
emerged of interest to science as a cause of food poisoning, was later considered as an
agent in chemical warfare or biological terrorism, and subsequently as a medical treatment for
involuntary muscle spasm. It is now routinely and voluntarily injected into consumer
foreheads during lunch breaks to temporarily keep the signs of ageing at bay, leaving it not at
all clear which populations now need to be protected against Botox®. Ironies are also evident
over an evolutionary time scale. Biologists are only now recognising the function of the viral
remnants within our DNA and the productive role played by viruses in ‘species development,
in the creation of new genes, and even in the evolution itself’ (MacPhail, 2004, p. 325), just at
the point when the value of biosecurity regimes for humans and for animals appear to be
premised on the impossible promise of developing disease-free populations.
Defining the materiality of what is a biological agent itself becomes a matter of some dark
humour for authorities seeking to govern biotechnological risks. As Brian Balmer asks in a
forthcoming paper, ‘which is more dangerous: the four page patent specification for VX nerve
gas or Nesquik milkshake powder?’ (Balmer, 2006, p. 691). The trajectories traced in the
paper suggest a more complicated answer than might first appear. Whilst Terry Olsen was
quickly arrested by the FBI and imprisoned for sending himself a mixture of sugar and
chocolate Nesquik he claimed was anthrax in the wake of the World Trace Centre attacks in
2001, the security implications of publishing the patent on the chemical warfare agent, VX, in
1975, is conversely treated with relative nonchalance by British Ministers. As I have written
about elsewhere, humour also features centrally in public debates about the claims made for
the future of biotechnology, in this case in speculations around the potential options for organ
transplantation (Davies, 2006). Here, humour is a device that challenges the universalising
claims made in the life sciences, relocating these through the contingencies and comedies of
inhabiting a singular and often unpredictable body. Again, these are not trivial exchanges, but
serve to de-reify expectations by drawing attention to the gaps that open up between personal
embodied experiences and entrepreneurial claims, as people reflect on what it might mean to
materially inhabit the new bodies that are proposed.
So, in tracing the speculative trajectories of the life sciences, I would argue there is an
opportunity for using humour and irony to think about the metaphors of life we evoke, the
kinds of subjectivities we engage, the performativity of the narratives we write, and the ways
in which we might stage more creative debates about the future of biotechnology. Recent
work by urban geographers on different strategies for engaging with the city demonstrates
just how imaginative some of these forms of research and writing can be in opening up ideas
about how to live cities differently (see for example Pinder, 2005). As the life sciences
increasingly shape the contours of our bodies, the boundaries of the states and the forms of
sociality we are likely to inhabit, we too need experimentation that opens up attention to the
inevitable subversions and inherent openness of the relations between biology, space and
society. Laughter might just turn out to be a good medicine, even if we don't have or want the
closure that a punchline would supply.
References
Bloomberg.com (24.5.2006) U.S. Stock-Index Futures Advance
<http://quote.bloomberg.com/apps/news?pid=10000103&sid=ahLZfuzf7cok&refer=news_inde
x> accessed 8/24/2006.
Balmer, B., 2006. A secret formula, a rogue patent and public knowledge about nerve gas:
secrecy as a spatial–epistemic tool. Social Studies of Science 36: 691-722.
Braun, B., 2006. Molecular geographies: 'emerging infectious diseases' and the geopolitics of
biosecurity. Paper presented at the Association of American Geographers Annual
Conference, Chicago, April 2006.
Brown, N. and Michael, M., 2003. A sociology of expectations: retrospecting prospects and
prospecting retrospects. Technology Analysis & Strategic Management, 15: 3 – 18.
Cooper, M., 2006a. Resuscitations: stem cells and the crisis of old age. Body and Society 12:
1-23.
Cooper, M., 2006b. Pre-empting emergence: the biological turn in the war on terror. Theory
Culture and Society 23: 113-135.
Davies, G., 2006. The sacred and the profane: biotechnology, rationality and public debate.
Environment and Planning A 38, 423-444.
Haraway, D., 1991. ‘A Cyborg Manifesto: science, technology, and socialist-feminism in the
late Twentieth Century. In: Simians, Cyborgs and Women: The Reinvention of Nature,
Routledge, New York, pp.149-181.
Jasanoff, S., 2005. Designs on nature: science and democracy in Europe and the United
States. Princeton University Press, London.
MacPhail, T., 2004. The viral gene: an undead metaphor recoding life. Science as Culture
13: 325-345.
Mabey, R., 2006. Nature Cure. Pimlico Press, London.
Meeker, J., 1997. The Comedy of Survival: Literary Ecology and the Play Ethic, 3rd edition.
University of Arizona Press, Tucson.
Mulkay, M., 1993. Rhetorics of Hope and Fear in the Great Embryo Debate. Social Studies
of Science, 23, 721–742.
Pinder, D., 2005. Arts of urban exploration. Cultural Geographies 12, 383-411.
Sunder Rajan, K., forthcoming. Lively Capital: biotechnologies, ethics and governance. Duke
University Press
The onion (18.7.2006) Stock watch <http://www.theonion.com/content/index/4229> accessed
24/08/2006
Acknowledgements
My thanks to Brian Balmer, Kezia Barker, Bruce Braun, David Demeritt, Andrew Leyshon and
Kaushik Sunder Rajan for sharing drafts of their ideas or being on the receiving end whilst I
tried out some of mine. My apologies to all that the end result is not particularly funny.
